Document Detail

Management of endometrial adenocarcinoma with cervical involvement.
MedLine Citation:
PMID:  1612507     Owner:  NLM     Status:  MEDLINE    
Seventy-seven patients with endometrial cancer with cervical involvement were treated at Memorial Sloan-Kettering Cancer Center from 1968 to 1982. Fractional curettage specimens showed that 25 patients (32%) had involvement of cervical stroma and 52 (68%) had only detached fragments of carcinoma present in endocervical curettings. Six patients treated for palliation only are excluded from analysis of treatment and survival. Our preferred treatment during the time interval studied consisted of preoperative whole pelvic radiotherapy followed by modified radical hysterectomy and bilateral salpingo-oophorectomy with post-operative intravaginal brachytherapy. This regimen was well tolerated by the 37 patients so treated. The remaining patients were treated with a variety of regimens, most commonly radiotherapy and simple hysterectomy (25 patients). With a mean follow-up among survivors of 97 months, disease-free survival is 72%. Mean time to relapse was 19 months, with 90% of relapses occurring within 40 months. Initial sites of relapse included abdomen, 9 (12.6%); lungs, 8 (11.3%); brain, 2 (2.8%); lateral pelvis, 2 (2.8%); and bone, 1 (1.4%). Clinicopathologic variables significantly related to risk of relapse included presence of extrauterine disease at surgery (P = 0.0001), extent of cervical involvement as determined prior to hysterectomy (P = 0.001), depth of myometrial invasion (P = 0.005), and papillary serous histology (P = 0.0002). Treatment of endometrial cancer with cervical involvement with combinations of radiotherapy and surgery is well tolerated and results in an excellent long-term disease-free survival and a low rate of pelvic relapse.
S C Rubin; W J Hoskins; P E Saigo; D Nori; B Mychalczak; D Chapman; J L Lewis
Related Documents :
18394687 - Clear cell carcinoma of the cervix: a multi-institutional review in the post-des era.
1452247 - A study of humoral factors in carcinoma cervix.
21711067 - Impact of clinical oral chemotherapy program on wastage and hospitalizations.
25057167 - On demand gamma-knife strategy can be safely combined with braf-inhibitors for the trea...
24123097 - On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma ...
23490907 - Excellent long-term disease control with modern radiotherapy techniques for stage i tes...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Gynecologic oncology     Volume:  45     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  1992 Jun 
Date Detail:
Created Date:  1992-07-24     Completed Date:  1992-07-24     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  294-8     Citation Subset:  IM    
Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / metabolism,  pathology,  therapy*
Cervix Uteri / pathology*
Combined Modality Therapy
Follow-Up Studies
Neoplasm Recurrence, Local
Neoplasm Staging
Survival Analysis
Uterine Neoplasms / metabolism,  pathology,  therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Gore-Tex Surgical Membrane: effectiveness as a barrier to inhibit postradical pelvic surgery adh...
Next Document:  Superficially invasive squamous cell carcinoma of the cervix.